Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
44 hedge funds and large institutions have $140M invested in Evelo Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
7% more funds holding
Funds holding: 41 → 44 (+3)
22% less capital invested
Capital invested by funds: $180M → $140M (-$39.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$454K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$254K |
| 3 |
Citigroup
New York
|
+$185K |
| 4 |
6CM
683 Capital Management
New York
|
+$179K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$440K |
| 2 |
Millennium Management
New York
|
-$180K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$107K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$58.2K |
| 5 |
E
Ergoteles
New York
|
-$57K |
EVLO Hedge Fund Activity: Q4 2022 in Review
44 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2022, worth a combined $140M — down 22% from $180M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EVLO positions and 6 closed out — a net gain of 3 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $454K. The largest seller was CVI Holdings, cutting an estimated $440K.
- 44 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2022, up from 41 in Q3 2022.
- Funds reported $140M of Evelo Biosciences, Inc. Common Stock stock for Q4 2022, down 22% quarter-over-quarter.
- 9 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of +3 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2022 was Fidelity Investments, an estimated $454K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2022 was CVI Holdings, an estimated $440K sold.
Based on aggregated 13F filings for Q4 2022.